Literature DB >> 10834306

Effects of natriuretic peptides (ANP, BNP, CNP) on catecholamine synthesis and TH mRNA levels in PC12 cells.

K Takekoshi1, K Ishii, K Isobe, F Nomura, T Nammoku, T Nakai.   

Abstract

Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and C-type natriuretic peptide (CNP) are present in adrenal chromaffin cells, and are co-secreted with catecholamines suggesting that these natriuretic peptides (NPs) may modulate functions of chromaffin cells in an autocrine and/or paracrine manner. Therefore, we investigated the effects of NPs on tyrosine hydroxylase (TH: a rate-limiting enzyme in biosynthesis of catecholamine) mRNA in rat pheochromocytoma PC12 cells. It was also determined whether the cyclic GMP/cGMP-dependent protein kinase (cGMP/PKG) pathway was involved in theses effects. Finally, we examined the effects of NPs on intracellular catecholamine content to confirm increase of catecholamine synthesis following TH mRNA induction. NPs (0.1 microM) induced significant increases of the TH mRNA (ANP= BNP> CNP). Also, the effects of NPs on TH mRNA were mimicked by 8-bromo cyclic GMP (1mM), and were blocked by KT5823 (1 microM) (inhibitor PKG) or LY83583 (1 microM) (guanylate cyclase inhibitor). Moreover, NPs were shown to induce significant increases of intracellular catecholamine contents (ANP= BNP> CNP). These findings suggest that NPs induced increases of TH mRNA through cGMP/PKG dependent mechanisms, which, in turn, resulted in stimulation of catecholamine synthesis in PC12 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834306     DOI: 10.1016/s0024-3205(00)00549-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Pathophysiology and Individualized Management of Vasovagal Syncope and Postural Tachycardia Syndrome in Children and Adolescents: An Update.

Authors:  Ying Liao; Junbao Du
Journal:  Neurosci Bull       Date:  2020-05-04       Impact factor: 5.203

2.  C-type natriuretic peptide in Parkinson's disease: reduced secretion and response to deprenyl.

Authors:  E A Espiner; J C Dalrymple-Alford; T C R Prickett; Y Alamri; T J Anderson
Journal:  J Neural Transm (Vienna)       Date:  2013-12-05       Impact factor: 3.575

3.  Plasma C-type natriuretic peptide as a predictor for therapeutic response to metoprolol in children with postural tachycardia syndrome.

Authors:  Jing Lin; Zhenhui Han; Hongxia Li; Selena Ying Chen; Xueying Li; Ping Liu; Yuli Wang; Chaoshu Tang; Junbao Du; Hongfang Jin
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

4.  Atrial Natriuretic Peptide Acts as a Neuroprotective Agent in in Vitro Models of Parkinson's Disease via Up-regulation of the Wnt/β-Catenin Pathway.

Authors:  Arianna Colini Baldeschi; Eugenia Pittaluga; Federica Andreola; Simona Rossi; Mauro Cozzolino; Giuseppe Nicotera; Gianluca Sferrazza; Pasquale Pierimarchi; Annalucia Serafino
Journal:  Front Aging Neurosci       Date:  2018-02-01       Impact factor: 5.750

5.  Baroreflex sensitivity predicts therapeutic effects of metoprolol on pediatric postural orthostatic tachycardia syndrome.

Authors:  Yaxi Cui; Yuanyuan Wang; Ping Liu; Yuli Wang; Junbao Du; Hongfang Jin
Journal:  Front Cardiovasc Med       Date:  2022-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.